GlassScriptPhysician profile
Jadiyer Acosta
NPI 1457766065
$16,974.99
in general payments reported to CMS, 2019-2025
25 companies · $3,305 in 2025
The $3,305 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,088 · 2020: $1,291 · 2021: $1,493 · 2022: $2,371 · 2023: $2,882 · 2024: $3,545 · 2025: $3,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,671 · Education: $60.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,671.38 |
| Education | $60.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,090.26 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,979.99 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,717.41 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,429.08 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $1,411.45 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $1,265.70 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $1,144.79 | 2019-2025 | Rexulti, Vyepti |
| Allergan, INC. | $861.36 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $812.11 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $749.80 | 2019-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $674.88 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $613.93 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $595.43 | 2022-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $588.95 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $231.89 | 2020-2023 | Trintellix |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $224.80 | 2022-2025 | Aplenzin |
| Almatica Pharma LLC | $171.99 | 2023-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $147.08 | 2021-2024 | Ingrezza |
| Acadia Pharmaceuticals INC | $63.99 | 2022-2023 | Nuplazid |
| Luye Pharma (USA) LTD. | $56.64 | 2025 | Erzofri Extended-Release |
| Shire North American Group INC | $55.25 | 2019 | |
| Tempus Ai, INC | $29.35 | 2024 | |
| Merck Sharp & Dohme LLC | $26.86 | 2022-2023 | Belsomra |
| Eisai INC. | $17.14 | 2020 | |
| Penumbra, INC. | $14.86 | 2023 | Penumbra System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jadiyer Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.